About the Neurotechnology Industry
Neurotechnology companies develop treatments and diagnostics for a range of brain and nervous system illnesses including: Alzheimer's disease, addiction, anxiety, attention disorders, depression, epilepsy, hearing loss, insomnia, obesity, pain, Parkinson's disease, schizophrenia, sleep disorders, stroke, traumatic brain and spinal cord injury among others.
According to The Neurotechnology Industry 2007 Report published by NeuroInsights:
-
Neurotech industry revenues rose 10% to $120.5 billion in 2006; this includes neuropharmaceutical revenues of $101 billion, neurodevice revenues of $4.5 billion, neurodiagnostic revenues of $15 billion.
-
Venture capital investment in neurotech rose 7.5% to $1.67 billion in 2006.
-
Since 1999, venture investment in neurotech has increased over 250%.
-
Brain-related illnesses afflict more than two billion people worldwide and 100 million in North America.
- There are over 500 drug, device and diagnostic neuroscience companies worldwide.
-
The annual economic burden of brain-related illnesses has reached more than $1 trillion in the U.S. and $2 trillion worldwide.
-
Aging populations are increasing the prevalence of brain-related illnesses creating unprecedented demand for treatments that delay, prevent and cure chronic neurological and psychiatric illnesses.
|
| Source: The Neurotechnology Industry 2007 Report : Market Analysis and Strategic Investment Guide published by NeuroInsights |
|
